Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.41298 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Natalia Kirsten und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. nat.ki…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Patient Reported Outcome Measures. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hidradenitis suppurativa is a chronic skin disease associated with significant disease burden. To assess patients’ treatment benefits, disease-specific outcomes measurement is needed. This study aimed to develop a questionnaire called Patient Benefit Index for hidradenitis suppurativa (PBI-HS). After an open-item survey, the items were condensed into a 26-item questionnaire on patient needs and benefits, with a 5-point Likert scale. In the validation study, construct and content validity, responsiveness, and feasibility of the questionnaire were assessed at 2 time points. A 26-item questionnaire was created following open-item generation by n = 72 patients. In the validation study, 3 items perceived as most relevant by patients were: “to be free of pain” (mean: 3.6 on a scale of 0–4), “to be free of inflammation” (mean: 3.6), “to have no more scars” (mean: 3.1). Significant correlations of PBI-HS at follow-up visit were found with the physical global assessment for hidradenitis suppurativa (HS-PGA) (r = –0.471; p = 0.000), number of inflammatory lesions (r = –0.359; p = 0.005), and DLQI (r = –0.383; p = 0.003), indicating less disease burden in patients with higher treatment benefits. The PBI-HS is a feasible and valid instrument to assess patient-reported treatment benefits in hidradenitis suppurativa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. nat.kirsten@gmx.de.
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
- Dermatologic Surgery Unit, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
- Clinic for Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
- Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
Zitieren
APA
Kirsten, N., Augustin, M., Blome, C., Topp, J., Schwager, R., Bechara, F. G., Girbig, G., Pinter, A., Anzengruber, F., Lindegaard, M., Zouboulis, C. C., & Otten, M. (2025). Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.41298
Vancouver
Kirsten N, Augustin M, Blome C, Topp J, Schwager R, Bechara FG, et al. Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.41298
BibTeX
@article{Kirsten2025,
author = {Kirsten, Natalia and Augustin, Matthias and Blome, Christine and Topp, Janine and Schwager, Richard and Bechara, Falk G and Girbig, Gefion and Pinter, Andreas and Anzengruber, Florian and Lindegaard, Mareen and Zouboulis, Christos C and Otten, Marina},
title = {Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.41298}
}
EUVIMED